Gastric and Gastroesophageal Adenocarcinoma
Sponsored by: GlobalData
- Gastric Cancer
- Gej Cancer
Date: 8 December
Days to go: 8
Time: 3PM London/10AM New York
Global Drug Forecast and Market Analysis to 2029
Gastric and GEJ cancer accounts for multiple subtypes of tumors, of which adenocarcinomas comprise 95% of cases which is why it was the focus of this report. Adenocarcinomas originate from the inner lining of the stomach and then progress to the outer layers and/or across to adjacent organs, eventually reaching the metastatic stage. Chemotherapy and surgery were the only treatment options available for these patients until 2010 with the approval of Roche’s Herceptin, an anti-HER2 monoclonal antibody, Eli Lilly’s Cyramza, an anti-VEGFR2 inhibitor and more recently the approval of Bristol-Myers Squibb’s Opdivo in Japan and South Korea, and Merck Co’s Keytruda in the US. These approvals allowed for the first sequential treatment approach within this indication.
Despite these approvals, overall prognosis is still poor with low survival rates for these patients. This could be attributed to various factors. Firstly, only Japan and South Korea have established screening programs which have effectively improved early stage diagnosis and prognosis for patients. The remaining markets within the 8MM* have a lower baseline incidence rate which would not warrant the same strategy and instead would require a more cost-effective strategy to screening in order to implement this approach. Secondly, there is a lack of options in the adjuvant and neoadjuvant settings which could improve treatment outcomes after surgery. Furthermore, patients in the HER2 positive setting are primarily treated with Herceptin, though this agent has had limited success and novel HER2 targeting agents will be required to compensate for Herceptin’s limitations. Then in the HER2 negative setting, chemotherapy remains the mainstay treatment strategy which is a major setback for these patients.
Therefore, the market is open to new entrants, and GlobalData is forecasting 9 candidates to launch, in addition to 5 label expansions through 2029 across the 8MM. Despite the patent expiries of the current market leading drugs, GlobalData is projecting a moderate compound annual growth rate (CAGR) of 9.3% across the 8MM between 2019-2029.
In this webinar Miguel Ferreira, MSc, Healthcare Analyst at GlobalData, will present the drug forecast and market analysis to 2029, drawing on key insights from GlobalData’s recently published report, Gastric and Gastroesophageal Adenocarcinoma: Global Drug Forecast and Market Analysis to 2029. The current treatment options and drug pipeline will be covered, including a discussion on GlobalData’s sales forecasts for the most impactful therapies. The webinar will cover insights from various key opinion leaders (KOLs) on the current treatment options, pipeline drugs, the unmet needs, and the most promising R&D strategies. Fern Barkalow, PhD, Senior Director of Oncology and Hematology at GlobalData will moderate the Q&A session following the presentation.
8MM*: US, France, Germany, Italy, Spain, UK, Japan and South Korea
Miguel Ferreira, MSc,
Oncology and Hematology Analyst
Miguel Ferreira, MSc, is an Oncology and Hematology and Analyst at GlobalData in London, where he primarily develops forecast models and reports for specific cancer indications and writes monthly insight pieces in ongoing pharmaceutical events relative to Oncology. Prior to his role at GlobalData, Miguel worked as a Clinical Trial Coordinator at University College London Hospital for in the SUMMIT study clinical trial. The SUMMIT study was the UK’s largest clinical trial to evaluate the implementation of blood tests and CT scans for lung cancer screening. Miguel completed his MSc in Cancer and Clinical Oncology at Barts Cancer Institute in 2018 following his BSc in Biomedical Science at the University of Essex.
Fern Barkalow, PhD,
Senior Director of Oncology and Hematology
Fern Barkalow, PhD, is the Senior Director of Oncology and Hematology at GlobalData in Boston. Fern has over 20 years of experience in the biopharmaceutical industry, as well as a research background in molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern then joined the database group at Incyte Pharmaceuticals where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then moved into the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs. Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine and Dentistry of New Jersey and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women’s Hospital.
Key Learning Objectives
- Learn how the Gastric and Gastroesophageal Adenocarcinoma market dynamics are expected to change between 2019 and 2029 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and South Korea)
- Gain in-depth insight about the late-stage Gastric and Gastroesophageal Adenocarcinoma pipeline, including the products that are expected to dominate the market and the key drivers behind these.
- Understand the unmet needs that key opinion leaders (KOLs) have identified in the Gastric and Gastroesophageal Adenocarcinoma treatment space and an analysis on whether the current pipeline will meet these needs.
- Learn about some of the key R&D strategies, growth drivers, and barriers in the Gastric and Gastroesophageal Adenocarcinoma market across the 8MM.
- Managers/Senior Managers
- Associate Directors
- Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers